This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, National Institute for Agricultural Research, National Institute of Health and Medical Research. Active years: 2023.
Company Filing History:
1 out of 331 
1 out of 285 
1 out of 1,853 
Years Active: 2023
Title: Jane Mea Natividad: Innovator in Metabolic Syndrome Treatment
Introduction
Jane Mea Natividad is a prominent inventor based in Paris, France. She has made significant contributions to the field of metabolic health through her innovative research and inventions. Her work focuses on the use of AhR agonists for the treatment of metabolic syndrome and associated disorders.
Latest Patents
Jane Mea Natividad holds a patent for the "Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders." This invention relates to the preventive or curative treatment of metabolic syndrome using AhR agonists or microorganisms that produce AhR agonists. Her patent represents a significant advancement in the approach to managing metabolic health.
Career Highlights
Throughout her career, Natividad has worked with esteemed institutions such as the Institut National de la Recherche Agronomique and Sorbonne Université. Her experience in these organizations has allowed her to develop her expertise and contribute to groundbreaking research in her field.
Collaborations
Jane has collaborated with notable professionals, including Harry Sokol and Bruno Michel Lamas. These partnerships have enriched her research and expanded the impact of her work in the scientific community.
Conclusion
Jane Mea Natividad is a trailblazer in the field of metabolic syndrome treatment, with her innovative patent paving the way for future advancements. Her contributions to research and collaboration with esteemed institutions highlight her commitment to improving health outcomes.